Loading clinical trials...
Loading clinical trials...
A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children With Hereditary Angioedema Who Are 2 to < 12 Years of Age
Conditions
Interventions
Berotralstat
Locations
15
Austria
Investigative Site #1
Vienna, Ontario, Austria
Investigative Site #1
Ottawa, Ontario, Canada
Investigative Site #3
Grenoble, France
Investigative Site #2
Marseille, France
Investigative Site #1
Paris, France
Investigative Site #1
Berlin, Germany
Start Date
October 25, 2022
Primary Completion Date
September 11, 2024
Completion Date
February 1, 2027
Last Updated
February 25, 2026
NCT03986021
NCT07489378
NCT06861257
NCT06905587
NCT06074666
NCT06960213
Lead Sponsor
BioCryst Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions